Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Strong Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Sell

Wall Street Data Solutions Rating

Buy

A

Arcellx, Inc. Common Stock (ACLX)

Biological Products, (no Disgnostic Substances)

https://www.arcellx.com

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

25 WEST WATKINS MILL ROAD, SUITE A
GAITHERSBURG, MD

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/04/2022

Market Cap

3,477,992,496

Shares Outstanding

48,690,000

Weighted SO

51,928,729

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

NUVL --.--%

VTYX --.--%

AMLX --.--%

DAWN --.--%

BMEA --.--%

Beta

0.2250

Last Div

0.0000

Range

30.88-75.1

Chg

-0.1600

Avg Vol

468304

Mkt Cap

3477992496

Exch

NASDAQ

Country

US

Phone

240 327 0603

DCF Diff

-14.5904

DCF

78.7604

Div Yield

0.0000

P/S

24.0284

EV Multiple

-44.3258

P/FV

7.1076

Div Yield %

0.0000

P/E

-64.2497

PEG

-0.9859

Payout

0.0000

Current Ratio

6.0052

Quick Ratio

6.0052

Cash Ratio

1.1353

DSO

8.0694

DIO

0.0001

Op Cycle

8.0695

DPO

549.4187

CCC

-541.3492

Gross Margin

0.9777

Op Margin

-0.5573

Pretax Margin

-0.3657

Net Margin

-0.3723

Eff Tax Rate

-0.0331

ROA

-0.0734

ROE

-0.1242

ROCE

-0.1249

NI/EBT

1.0181

EBT/EBIT

0.6562

EBIT/Rev

-0.5573

Debt Ratio

0.1012

D/E

0.1525

LT Debt/Cap

0.0895

Total Debt/Cap

0.1323

Int Coverage

-283.0386

CF/Debt

-0.2693

Equity Multi

1.5073

Rec Turnover

45.2328

Pay Turnover

0.6643

Inv Turnover

999999.9999

FA Turnover

2.0578

Asset Turnover

0.1971

OCF/Share

-0.3739

FCF/Share

-0.8011

Cash/Share

9.6586

OCF/Sales

-0.1382

FCF/OCF

2.1427

CF Coverage

-0.2693

ST Coverage

-0.7574

CapEx Coverage

-0.8751

Div&CapEx Cov

-0.8751

P/BV

7.1076

P/B

7.1076

P/S

24.0284

P/E

-64.2497

P/FCF

-81.1194

P/OCF

-173.0407

P/CF

-173.0407

PEG

-0.9859

P/S

24.0284

EV Multiple

-44.3258

P/FV

7.1076

DPS

0.0000

Latest Headlines (EST)

Benzinga Jan 04, 14:08 Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 Benzinga Jan 04, 12:00 Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know Benzinga Dec 11, 14:33 Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say Benzinga Dec 11, 14:33 Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say Zacks Investment Research Nov 06, 14:36 Roblox (RBLX) to Report Q3 Earnings: What's in the Cards?

Revenue Product Segmentation